Abstract
Objective. Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases. Methods. Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings. Results. Five themes pertaining to drug safety measurement emerged. Conclusion. Current approaches have failed to include data from the patient’s perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.
Original language | English (US) |
---|---|
Pages (from-to) | 1053-1058 |
Number of pages | 6 |
Journal | Journal of Rheumatology |
Volume | 46 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2019 |
Keywords
- Clinical trials disease-modifying antirheumatic drugs
- OMERACT
- Patient satisfaction
- Risk assessment
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology